人民财讯12月9日电，富士莱（301258）12月9日公告，公司于近日收到国家药品监督管理局签发的关于 硫辛酸片的《药品注册证书》。该药品用于糖尿病周围神经病变引起的感觉异常。 ...

证券代码：301258 证券简称：富士莱 公告编号：2025-069 苏州富士莱医药股份有限公司 关于公司获得硫辛酸片药品注册证书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 苏州富士莱医药股份有限公司（以下简称"公司"）于近日收到国家药品监 督管理局签发的关于硫辛酸片的《药品注册证书》。现将相关情况公告如下： 一、获批产品的基本信息 是否处方药：是 申请事项：药品注册（境内生产） 注册分类：化学药品 3 类 药品批准文号：国药准字 H20256163\国药准字 H20256164 药品批准有效期：至 2030 年 12 月 2 日 上市许可持有人：苏州富士莱医药股份有限公司 英文名称： Thioctic Acid Tablets 剂型：片剂 药品名称：硫辛酸片 规格：0.2g；0.6g 硫辛酸片适应症为：用于糖尿病周围神经病变引起的感觉异常。 三、对公司的影响及风险提示 公司硫辛酸片获得国家药监局的药品注册证书，丰富了公司的产品线，有助 于提升公司产品的市场竞争力，对公司的经营业绩产生积极的影响。由于医药产 品的行业特点，该药品未来销售情况可能受到政 ...

Core Viewpoint - The implementation of the new national standard for electric bicycles, effective December 1, 2025, marks a significant regulatory shift affecting approximately 380 million electric bicycle owners in China, emphasizing safety and efficiency over speed [5][8][25]. Regulatory Changes - The new standard limits the maximum speed of electric bicycles to 25 km/h and introduces stricter requirements for battery safety, including flame retardancy and traceability throughout the vehicle's lifecycle [9][8]. - Key components such as non-metal materials and electrical circuits must meet enhanced fire resistance standards, and the total mass of plastic used in the bicycle must not exceed 5.5% of the total vehicle weight [9][8]. - The standard allows for a transition period, with vehicles produced under the old standard permitted to be sold until August 31, 2025, and consumers will not be forced to discard non-compliant vehicles [9][10]. Market Impact - The new regulations are expected to lead to an increase in production costs by approximately 600-900 yuan per unit, which may result in higher retail prices for electric bicycles that were previously available for under 3000 yuan [21][19]. - The dual impact of the new standard and the "old-for-new" subsidy policy is anticipated to drive rapid growth in the electric bicycle industry, with companies like Yadea, Aima, and Ninebot reporting significant revenue increases [18][19]. User Behavior and Demand - Electric bicycles are a primary mode of transportation for many, with about half of users relying on them for commuting and shopping, valuing economic efficiency, convenience, and reliability [21][25]. - The new speed limit and safety features may affect the efficiency of delivery workers and commuters, who prioritize speed and endurance in their daily operations [21][25]. Public Reaction - The introduction of the new standard has sparked widespread discussion among users, focusing on technical performance, safety concerns regarding battery reliability, and the reasonableness of the 25 km/h speed limit [23][24]. - Despite mixed opinions, the overarching sentiment acknowledges the necessity of the new regulations as a transformative step towards a safer and more regulated electric bicycle market [26][27].

Group 1: Financial Management and Risk Control - The significant increase in accounts payable is primarily due to the investment in the "Fujilai (Shandong) Specialty API and Intermediate CMO/CDMO Construction Project" [2] - The company aims to ensure project funding needs while controlling debt scale and financial risks through coordinated project construction and financial management [2] - The company has implemented measures such as credit assessment and collection tracking to optimize accounts receivable management and reduce bad debt risk [3] Group 2: Investment Strategies and Returns - The company utilizes idle funds for entrusted financial management to enhance the efficiency of fund usage and improve returns, without affecting normal operations [3] - The increase in income tax expenses is mainly due to a significant rise in investment income during the current period [3] Group 3: Inventory and Supply Chain Management - The company plans to continuously optimize inventory structure and strengthen market trend analysis to adapt to changes in market demand [3] - The reduction in inventory balance since the beginning of the year has positively impacted profits due to the reversal of inventory impairment provisions [3] Group 4: Project Development and Future Outlook - The "Fujilai (Shandong) Specialty API and Intermediate CMO/CDMO Construction Project" is progressing as per the scheduled timeline, with expected contributions to revenue and profit post-production [5] - The company is focused on enhancing its core competitiveness in the specialty API and intermediate sector to inject new momentum into sustainable development [5] Group 5: Shareholder Communication and Governance - The company emphasizes compliance with legal regulations regarding shareholder reduction plans and will ensure timely information disclosure [2] - The sustainability of government subsidies remains uncertain, and the company is monitoring potential new support projects or policies [3]

证券代码：301258 证券简称：富士莱 公告编号：2025-068 苏州富士莱医药股份有限公司 关于参加 2025 苏州上市公司投资者集体接待日活动 的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 为进一步加强与投资者的互动交流，苏州富士莱医药股份有限公司（以下简 称"公司"）将参加"2025 苏州上市公司投资者集体接待日"活动，现将相关 事项公告如下： 出席本次网上集体接待日的人员有：公司董事会秘书兼财务总监卞爱进先生； 证券事务代表吴晨钧先生。 2025 年 11 月 27 日 本次活动将采用网络远程的方式举行，投资者可登录"全景路演" （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2025 年 12 月 2 日（星期二，15:30-17:00）。 届时公司将在线就投资者关心的问题，与投资者进行沟通与交流，欢迎广大 投资者踊跃参与！ 特此公告。 苏州富士莱医药股份有限公司 董事会 ...

证券代码：301258 证券简称：富士莱 公告编号：2025-067 苏州富士莱医药股份有限公司 2025 年第三次临时股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 特别提示： 1.本次股东会不存在否决议案的情形。 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开情况 （一）会议召开的时间 1、现场会议时间：2025 年 11 月 26 日下午 14:30。 2、网络投票时间：2025 年 11 月 26 日 （1）通过深圳证券交易所交易系统进行网络投票的时间为： 2025 年 11 月 26 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00； （2）通过深圳证券交易所互联网投票系统进行网络投票的时间为 2025 年 11 月 26 日 9:15-15:00。 （二）现场会议召开地点：江苏省常熟市新材料产业园海旺路 16 号 （三）股权登记日：2025 年 11 月 20 日 （四）会议召开方式：现场表决和网络表决相结合的方式。同一表决权只能 选择现场投票或网络投票表决方式中的一种，不能重复投票，同一 ...

上海兰迪（苏州）律师事务所 法律意见书 上海兰迪（苏州）律师事务所 关于苏州富士莱医药股份有限公司 2025 年第三次临时股东会的 法律意见书 地址：苏州市姑苏区人民路 3110 号国发大厦南楼 907 电话：0512-67872033 上海兰迪（苏州）律师事务所 法律意见书 上海兰迪（苏州）律师事务所 关于苏州富士莱医药股份有限公司 2025 年第三次临时股东会的 法律意见书 致：苏州富士莱医药股份有限公司 上海兰迪（苏州）律师事务所（以下简称"本所"）接受苏州富士莱医药股份有 限公司（以下简称"公司"）的委托，就贵公司召开的 2025 年第三次临时股东会 （以下简称"本次股东会"）进行见证并就相关事宜出具本法律意见书。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下 简称"《股东会规则》"）、《深圳证券交易所上市公司股东会网络投票实施细则》 以及《苏州富士莱医药股份有限公司章程》（以下简称"《公司章程》"）等规定， 就本次股东会的召集和召开程序、召集人资格和出席会议人员资格、会议表决程序和 表决结果等相关事 ...

（文章来源：证券日报） 证券日报网讯富士莱11月25日在互动平台回答投资者提问时表示，公司与恒瑞医药的合作进展顺利，公 司期待以此为基础，未来拓展更多合作机会。 ...

Core Viewpoint - Fujifilm announced on November 25 that it has received the GMP compliance inspection result notification from the Jiangsu Provincial Drug Administration, confirming that its active pharmaceutical ingredient, Apatinib Mesylate, meets GMP standards, laying a solid foundation for future commercialization [1] Group 1 - The company has successfully passed the GMP compliance inspection for its raw material drug Apatinib Mesylate [1] - This compliance is crucial for the subsequent commercialization of the product [1]

Core Viewpoint - Fujilai plans to deepen its existing business layout in the coming year, actively seizing market opportunities through product structure optimization, cost reduction, efficiency enhancement, and steady market expansion to achieve sustainable development and stable performance improvement [1] Group 1 - The company aims to optimize its product structure [1] - The company is focused on cost reduction and efficiency enhancement [1] - The company intends to steadily expand its market presence [1]